Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Evofem Biosciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0.45
8.24
16.8
18.2
19.4
20.2
Cost of revenue
0
0.47
4.06
4.42
6.51
3.83
4.62
Gross profit
0
-0.02
4.19
12.4
11.7
15.5
15.6
Research and development
6.58
23.5
43.4
22.2
17.1
33.1
25
2.94
1.85
Selling and marketing
10.2
56.5
113
44
11.7
9.18
9.68
General and administrative
5.46
12.1
34.2
20.3
30.1
24.7
27.6
15
11.6
7.39
Operating expenses
12
35.7
77.6
52.7
104
Operating income
-12
-35.7
-77.6
-52.7
-104
-167
-84.1
-17.8
-7.68
3.37
Interest expense
1.04
0
2.06
2.67
2.18
2.27
2.24
2.37
Interest income
0.06
0.13
0.13
0.46
0.17
0.02
0.09
0.03
0.02
0.02
Other non-operating income
-69.6
-48.1
-27.3
-38.7
-38.4
7.47
70.8
-1.18
-2.98
Pre-tax income
-105
-126
-80
-142
-205
-76.7
53
-8.86
0.39
Income tax
0
0
0
0
0
0.02
0.04
0.02
0
Net income
-13
-105
-126
-80
-142
-205
-76.7
53
-8.86
0.39
EBITDA
-12
-35.4
-77.4
-52.5
-103
-166
-83.1
-17.4
-7.65
3.39
EPS, basic
-124,890.00
-95,543.00
-9,832.00
-3,409.00
-3,631.00
-2,706.00
-153.47
9.50
-0.11
0.00
EPS, diluted
-124,890.00
-95,543.00
-9,832.00
-3,409.00
-3,631.00
-2,706.00
-153.47
0.05
-0.11
0.00
Shares, basic (weighted)
0
0
0.01
0.02
0.04
0.08
0.51
5.27
80
124
Shares, diluted (weighted)
0
0
0.01
0.02
0.04
0.08
0.51
1,073
80
6,422
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
11.5
1.21
1.33
15.6
48.9
7.73
2.77
0.58
0.74
0.58
Receivables
0
1.07
6.45
1.13
5.74
9.83
12.5
Inventory
0
7.16
7.67
5.38
1.7
1.58
1.13
Other current assets
1.03
0.65
0.72
2.31
18.1
3.23
2.22
1.2
0.18
0.06
Total current assets
12.5
2.35
2.48
26.4
97.7
30.1
12.7
9.21
13.6
15.3
Property, plant and equipment
0.11
0.85
0.59
0.39
4.33
5.77
3.94
1.2
0.46
0.42
Lease right-of-use assets
0
0.16
6.86
5.4
4.41
0.11
0.09
0.18
Intangible assets
9.6
4.35
Other non-current assets
0.75
0.94
1.32
1.05
1.2
4.12
0.04
0.04
0.04
Total assets
12.8
3.95
4.01
28.3
110
42.5
25.2
10.6
23.8
20.3
Accounts payable
0.5
9
8.88
6.01
10.6
10.3
15
17
16.2
13.2
Accrued liabilities
0.4
12.1
11.5
2.78
4.48
8.37
4.12
4.23
5.51
1.29
Deferred revenue
3.2
0.4
Short-term debt
0.14
0.15
Total current liabilities
0.9
103
27.3
12.7
77.3
138
93.8
72.5
80.4
84.8
Lease liabilities
0
6.03
4.42
3.13
0.01
0.01
0.05
Other non-current liabilities
0.17
0
0
Total liabilities
194
104
27.4
12.7
109
142
97
72.5
90.3
89.7
Paid-in capital
138
17.7
410
529
657
751
817
823
829
832
Retained earnings
-126
-307
-433
-513
-655
-861
-939
-889
-898
-897
Other comprehensive income
0
5.09
49.5
-0.85
-2.63
-8.82
Shareholders' equity
-181
-290
-23.4
15.6
1.35
-104
-71.8
-66.5
-71.3
-74.3
Total equity
-181
-290
-23.4
15.6
1.35
-104
-71.8
-66.5
-71.3
-74.3
Total liabilities and equity
12.8
3.95
4.01
28.3
110
42.5
25.2
10.6
23.8
20.3
Shares outstanding
0
0
0.02
0.03
0.05
0.09
1.07
21.8
113
127
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-13
-105
-126
-80
-142
-205
-76.7
53
-8.86
0.39
Depreciation and amortization
0.07
0.24
0.26
0.26
0.3
1.02
1.02
0.48
0.03
0.02
Stock-based compensation
1.08
0.86
17.8
8.58
12.7
8.9
3.31
1.19
0.85
0.17
Deferred income tax
0
0
0
0
0
0
Change in receivables
0
-1.07
-5.38
5.32
-4.61
-4.09
-2.65
Change in inventory
0
-6.01
-0.02
1.57
2.11
0.06
-0.26
Change in payables
-5.44
7.05
3.8
-2.93
4.13
-0
4.47
4.09
-0.91
0.18
Cash from operations
-16.3
-19.2
-56.5
-55.1
-105
-147
-70.4
-8.97
-3.89
-1.99
Capital expenditures
-0.01
-0.01
-0.16
-2.25
-2.94
-0.34
-0
-0.01
-0.01
Acquisitions
-0.56
Sales and maturities of investments
0
8.23
0
0
Cash from investing
0
0.24
2.14
-8.12
6.23
-2.69
-0.34
-0
-0.57
-0.06
Debt issued
0
50
0
11.5
5.64
Debt repaid
-0.54
0
-5.89
-1.15
-0.5
Stock issued
0.03
0
20
0.1
0.08
0
0
Share buybacks
0
-0.02
Dividends paid
-0.2
Cash from financing
-10
9.21
54.4
78.1
154
90.7
61.9
4.78
4.62
1.89
Net change in cash
-26.3
-9.79
0.06
14.9
55.6
-58.7
-8.81
-4.2
0.16
-0.16
Free cash flow
-19.2
-56.5
-55.3
-107
-150
-70.8
-8.97
-3.9
-2
Interest paid
0.97
0.02
0
0
1.39
0.7
0.34
0.16
0.02
Income taxes paid
0
0
0
0
0.01
0.03
0
0.01
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.01 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
75.5%
Gross profit / revenue.
Operating margin
-15.3%
Operating income / revenue.
EBITDA margin
-15.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-84.7%
Pre-tax income / revenue.
Net margin
-84.7%
Net income / revenue.
FCF margin
-2.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2.6%
Cash from operations / revenue.
Return on assets (ROA)
-203.2%
Net income / average total assets.
Stock-based pay / revenue
0.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.0%
Capital expenditures / revenue.
D&A / revenue
0.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
4.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
6.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
114.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
0.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
7.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-14.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-6.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-28.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
7,927.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2,229.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
1,004.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.07x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.11
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.13
Revenue / diluted weighted shares.
FCF per share
-$0.00
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.66
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.06x
Market cap / revenue.
EV/Sales
0.04x
Enterprise value / revenue.
FCF yield
-45.0%
Free cash flow / market cap.
Earnings yield
-1,441.0%
Net income / market cap (the inverse of P/E).
What was Evofem Biosciences, Inc.'s revenue in fiscal 2025?
Evofem Biosciences, Inc. reported revenue of $20.2M for fiscal 2025, 4.2% higher than the year before.
Was Evofem Biosciences, Inc. profitable in fiscal 2025?
Yes. Net income was $391.0K, a net margin of 1.9%.
How much free cash flow did Evofem Biosciences, Inc. generate in fiscal 2025?
Cash from operations of $2.0M minus capital expenditures of $5.0K left free cash flow of -$2.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.